hypericin has been researched along with Necrosis in 40 studies
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to investigate the hypothesis that radioiodinated hypericin (131I-Hyp) may inhibit residual tumor recurrence after microwave ablation (MWA) on rat orthotopic liver allograft sarcoma models." | 7.83 | Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy. ( Gao, L; Gao, M; Ma, T; Ni, Y; Shan, X; Shao, H; Xu, K; Yao, N; Zhang, J, 2016) |
| "Hypericin has an excellent necrosis-specific targeting capacity; thus, we explored small-molecular tumor necrosis therapy (SMTNT) for inhibiting tumor growth in rodent tumor models." | 7.81 | Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models. ( Feng, Y; Gao, M; Huang, D; Jiang, C; Jiang, X; Jing, S; Li, Y; Liu, W; Ni, Y; Peng, F; Wang, X; Zhang, D; Zhang, J, 2015) |
| "We determined whether sodium cholate (NaCh) could act as a solubilizing agent for the necrosis avid iodine-123-labeled hypericin ((123)I-Hyp) and investigated biodistribution and targetability of this formulation in rabbits with acute myocardial infarction (AMI)." | 7.81 | Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction. ( Cona, MM; Feng, Y; Li, Y; Ni, Y; Oyen, R; Verbruggen, A; Zhang, J, 2015) |
| "Hypericin (HYP) has been found avid to necrosis in small animal studies." | 7.81 | Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis. ( Ni, Y; Qi, X; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015) |
| "The formulation of radioiodinated hypericin/hypericin appears crucial for its physical property, biodistribution, necrosis avidity and tumoricidal effects." | 7.80 | Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. ( Alpizar, YA; Bauwens, M; Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Oyen, R; Sun, Z; Talavera, K; Verbruggen, A; Zhang, J, 2014) |
| "Hypericin (Hyp) is newly recognized as a necrosis avid agent, but its poor solubility imposes a great hindrance in clinical application." | 7.80 | Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis. ( Cona, MM; Fang, Z; Gao, M; Ji, Y; Jiang, C; Jiang, X; Li, Y; Liu, W; Ni, Y; Sun, Z; Wang, J; Wang, Q; Wang, X; Yao, N; Yin, Z; Zhan, Y; Zhang, J, 2014) |
| "Hypericin, a potent necrosis avid agent, features a peculiar affinity for necrotic tissue." | 7.74 | Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. ( De Witte, PA; Ni, Y; Van de Putte, M, 2008) |
| "Mono-[(123)I]iodohypericin ([(123)I]MIH) has been reported to have high avidity for necrosis." | 7.74 | Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. ( Bormans, G; Feng, Y; Fonge, H; Mortelmans, L; Ni, Y; Nuyts, J; Verbruggen, A; Vunckx, K; Wang, H, 2008) |
| "The results suggest that hypericin derivatives may serve as powerful necrosis-avid diagnostic agents for assessment of tissue viability." | 7.73 | First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. ( Bormans, GM; Chen, F; de Witte, PA; Huyghe, D; Marchal, G; Mortelmans, L; Ni, Y; Nuyts, J; Verbeke, K; Verbruggen, AM, 2006) |
| "Photosensitization of HEC1-B cells with a low concentration of hypericin and doses of light below 10 J/cm(2) caused cell death (apoptosis occurred mainly at doses between 2 and 5 J/cm(2), whereas necrosis prevailed above 6 J/cm(2))." | 7.71 | Molecular aspects of photodynamic therapy: low energy pre-sensitization of hypericin-loaded human endometrial carcinoma cells enhances photo-tolerance, alters gene expression and affects the cell cycle. ( Coppola, E; Palumbo, G; Quarto, M; Varriale, L; Veneziani, BM, 2002) |
| "Here we report that photoactivated hypericin can induce either apoptosis or necrosis in HeLa cells." | 7.70 | Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis. ( Agostinis, P; Assefa, Z; Courtois, S; de Witte, P; Declercq, W; Merlevede, W; Vandenabeele, P; Vandenheede, JR; Vantieghem, A, 1998) |
| "Hypericin has been widely studied as a potent photosensitizer for photodynamic therapy in both preclinical and clinical settings." | 6.49 | Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging. ( Chen, F; Jiang, B; Ni, Y; Wang, J, 2013) |
| "In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits with VX2 tumors." | 5.42 | Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. ( Chen, F; Dai, X; Li, Y; Ni, Y; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015) |
| "Hypericin was radiolabeled with I using iodogen as oxidant, and (99m)Tc-Sestamibi was prepared from a commercial kit and radioactive sodium pertechnetate." | 5.39 | Comparative study of iodine-123-labeled hypericin and (99m)Tc-labeled hexakis [2-methoxy isobutyl isonitrile] in a rabbit model of myocardial infarction. ( Chen, F; Cona, MM; Feng, Y; Gheysens, O; Li, Y; Ni, Y; Nuyts, J; Oyen, R; Rezaei, A; Van Slambrouck, K; Verbruggen, A; Vunckx, K; Zhou, L, 2013) |
| " This would result in toxic melanin precursors (of an indolic and phenolic nature) leaking into the cytoplasm which in turn leads to cell death." | 5.35 | Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. ( Davids, LM; Kacerovská, D; Kidson, SH; Kleemann, B; Pizinger, K, 2008) |
| "Necrosis was the principal mode of cell death despite different PDT doses and the absence of anti-apoptotic Bcl-2 expression, even if the same condition induced caspase-3 activity at similar toxicity in HeLa cells." | 5.34 | Necrosis predominates in the cell death of human colon adenocarcinoma HT-29 cells treated under variable conditions of photodynamic therapy with hypericin. ( Fedorocko, P; Hofmanová, J; Horváth, V; Jamborová, E; Kleban, J; Kozubík, A; Mikes, J; Sacková, V; Vaculová, A, 2007) |
| " This study aimed to investigate the hypothesis that radioiodinated hypericin (131I-Hyp) may inhibit residual tumor recurrence after microwave ablation (MWA) on rat orthotopic liver allograft sarcoma models." | 3.83 | Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy. ( Gao, L; Gao, M; Ma, T; Ni, Y; Shan, X; Shao, H; Xu, K; Yao, N; Zhang, J, 2016) |
| "Hypericin has an excellent necrosis-specific targeting capacity; thus, we explored small-molecular tumor necrosis therapy (SMTNT) for inhibiting tumor growth in rodent tumor models." | 3.81 | Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models. ( Feng, Y; Gao, M; Huang, D; Jiang, C; Jiang, X; Jing, S; Li, Y; Liu, W; Ni, Y; Peng, F; Wang, X; Zhang, D; Zhang, J, 2015) |
| "Hypericin (Hy) has shown great promise as a necrosis-avid agent in cancer imaging and therapy." | 3.81 | Evaluation of hypericin: effect of aggregation on targeting biodistribution. ( Gao, M; Huang, D; Ji, Y; Jiang, C; Li, Y; Liu, W; Liu, X; Ni, Y; Sun, Z; Yao, N; Yin, Z; Zhang, J, 2015) |
| "Hypericin (HYP) has been found avid to necrosis in small animal studies." | 3.81 | Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis. ( Ni, Y; Qi, X; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015) |
| "We determined whether sodium cholate (NaCh) could act as a solubilizing agent for the necrosis avid iodine-123-labeled hypericin ((123)I-Hyp) and investigated biodistribution and targetability of this formulation in rabbits with acute myocardial infarction (AMI)." | 3.81 | Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction. ( Cona, MM; Feng, Y; Li, Y; Ni, Y; Oyen, R; Verbruggen, A; Zhang, J, 2015) |
| "The formulation of radioiodinated hypericin/hypericin appears crucial for its physical property, biodistribution, necrosis avidity and tumoricidal effects." | 3.80 | Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. ( Alpizar, YA; Bauwens, M; Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Oyen, R; Sun, Z; Talavera, K; Verbruggen, A; Zhang, J, 2014) |
| "Collar-induced carotid atherosclerosis ApoE knockout mice were imaged with (99m)Tc-AnxAF568 SPECT-CT to study apoptosis and sequentially with PET-CT following (124)I-Hypericin ((124)I-Hyp) injection to visualize necrosis." | 3.80 | In vivo molecular imaging of apoptosis and necrosis in atherosclerotic plaques using microSPECT-CT and microPET-CT imaging. ( Bauwens, M; Bucerius, J; De Saint-Hubert, M; Deckers, N; Douma, K; Drummen, M; Granton, P; Hendrikx, G; Kusters, D; Mottaghy, FM; Reutelingsperger, CP, 2014) |
| "To study the effect of co-injecting unlabelled hypericin (Hyp) on biodistribution, necrosis uptake and tumour retention of iodine-123 or iodine-131 labelled hypericin ((123/131)I-Hyp), a necrosis avid agent for an anticancer radiotherapy." | 3.80 | Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations. ( Chen, F; Cona, MM; Feng, Y; Li, J; Ni, Y; Oyen, R; Verbruggen, A; Witte, Pd, 2014) |
| "Hypericin (Hyp) is newly recognized as a necrosis avid agent, but its poor solubility imposes a great hindrance in clinical application." | 3.80 | Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis. ( Cona, MM; Fang, Z; Gao, M; Ji, Y; Jiang, C; Jiang, X; Li, Y; Liu, W; Ni, Y; Sun, Z; Wang, J; Wang, Q; Wang, X; Yao, N; Yin, Z; Zhan, Y; Zhang, J, 2014) |
| "Significant differences in hypericin fluorescence were found in necrosis, viable tumor and normal liver tissue in decreasing order (P < ." | 3.74 | Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. ( Chen, F; de Witte, PA; Ni, Y; Van de Putte, M; Wang, H, 2008) |
| "Mono-[(123)I]iodohypericin ([(123)I]MIH) has been reported to have high avidity for necrosis." | 3.74 | Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. ( Bormans, G; Feng, Y; Fonge, H; Mortelmans, L; Ni, Y; Nuyts, J; Verbruggen, A; Vunckx, K; Wang, H, 2008) |
| "Hypericin, a potent necrosis avid agent, features a peculiar affinity for necrotic tissue." | 3.74 | Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. ( De Witte, PA; Ni, Y; Van de Putte, M, 2008) |
| "In this proof-of-principle study, the necrosis avid agent hypericin was investigated as a potential indicator for early therapeutic response following radiofrequency ablation (RFA) of murine liver tumors." | 3.74 | Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. ( Chen, F; De Witte, PA; Ni, Y; Van de Putte, M; Wang, H, 2008) |
| "The results suggest that hypericin derivatives may serve as powerful necrosis-avid diagnostic agents for assessment of tissue viability." | 3.73 | First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. ( Bormans, GM; Chen, F; de Witte, PA; Huyghe, D; Marchal, G; Mortelmans, L; Ni, Y; Nuyts, J; Verbeke, K; Verbruggen, AM, 2006) |
| "Photosensitization of HEC1-B cells with a low concentration of hypericin and doses of light below 10 J/cm(2) caused cell death (apoptosis occurred mainly at doses between 2 and 5 J/cm(2), whereas necrosis prevailed above 6 J/cm(2))." | 3.71 | Molecular aspects of photodynamic therapy: low energy pre-sensitization of hypericin-loaded human endometrial carcinoma cells enhances photo-tolerance, alters gene expression and affects the cell cycle. ( Coppola, E; Palumbo, G; Quarto, M; Varriale, L; Veneziani, BM, 2002) |
| "Here we report that photoactivated hypericin can induce either apoptosis or necrosis in HeLa cells." | 3.70 | Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis. ( Agostinis, P; Assefa, Z; Courtois, S; de Witte, P; Declercq, W; Merlevede, W; Vandenabeele, P; Vandenheede, JR; Vantieghem, A, 1998) |
| "Hypericin has been widely studied as a potent photosensitizer for photodynamic therapy in both preclinical and clinical settings." | 2.49 | Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging. ( Chen, F; Jiang, B; Ni, Y; Wang, J, 2013) |
| " Their biodistribution and pharmacokinetic properties were determined in rat models of induced necrosis." | 1.43 | Effects of skeleton structure on necrosis targeting and clearance properties of radioiodinated dianthrones. ( Feng, Y; Gao, M; Huang, D; Jiang, C; Ni, Y; Shao, H; Sun, Z; Wang, X; Yang, S; Yin, Z; Zhang, D; Zhang, J, 2016) |
| "In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits with VX2 tumors." | 1.42 | Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. ( Chen, F; Dai, X; Li, Y; Ni, Y; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015) |
| "Hypericin was radiolabeled with I using iodogen as oxidant, and (99m)Tc-Sestamibi was prepared from a commercial kit and radioactive sodium pertechnetate." | 1.39 | Comparative study of iodine-123-labeled hypericin and (99m)Tc-labeled hexakis [2-methoxy isobutyl isonitrile] in a rabbit model of myocardial infarction. ( Chen, F; Cona, MM; Feng, Y; Gheysens, O; Li, Y; Ni, Y; Nuyts, J; Oyen, R; Rezaei, A; Van Slambrouck, K; Verbruggen, A; Vunckx, K; Zhou, L, 2013) |
| "Hypericin was conjugated to biotin-ethylenediamine in a straightforward coupling method using n-hydroxysuccinimide and dicyclohexylcarbodiimide." | 1.38 | Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy. ( Bauwens, M; Bormans, G; de Witte, P; Marysael, T; Ni, Y; Rozenski, J, 2012) |
| " This would result in toxic melanin precursors (of an indolic and phenolic nature) leaking into the cytoplasm which in turn leads to cell death." | 1.35 | Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. ( Davids, LM; Kacerovská, D; Kidson, SH; Kleemann, B; Pizinger, K, 2008) |
| "Necrosis was the principal mode of cell death despite different PDT doses and the absence of anti-apoptotic Bcl-2 expression, even if the same condition induced caspase-3 activity at similar toxicity in HeLa cells." | 1.34 | Necrosis predominates in the cell death of human colon adenocarcinoma HT-29 cells treated under variable conditions of photodynamic therapy with hypericin. ( Fedorocko, P; Hofmanová, J; Horváth, V; Jamborová, E; Kleban, J; Kozubík, A; Mikes, J; Sacková, V; Vaculová, A, 2007) |
| " However, the tumors administered with a initial dose of CX at 24-h post-PDT had no tumor control." | 1.33 | Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. ( Olivo, M; Soo, KC; Yee, KK, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.00) | 18.2507 |
| 2000's | 15 (37.50) | 29.6817 |
| 2010's | 22 (55.00) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Han, X | 1 |
| Taratula, O | 2 |
| Xu, K | 4 |
| St Lorenz, A | 1 |
| Moses, A | 1 |
| Jahangiri, Y | 1 |
| Yu, G | 1 |
| Farsad, K | 1 |
| Duan, X | 1 |
| Yin, Z | 6 |
| Jiang, C | 8 |
| Jin, Q | 3 |
| Zhang, D | 4 |
| Sun, Z | 8 |
| Ye, W | 1 |
| Zhang, J | 13 |
| Kong, M | 1 |
| Jiang, X | 3 |
| Li, Y | 8 |
| Gao, M | 6 |
| Yao, N | 4 |
| Huang, D | 4 |
| Wang, X | 4 |
| Fang, Z | 2 |
| Liu, W | 4 |
| Ni, Y | 23 |
| Cona, MM | 6 |
| Feng, Y | 8 |
| Chen, F | 8 |
| Vunckx, K | 2 |
| Zhou, L | 1 |
| Van Slambrouck, K | 1 |
| Rezaei, A | 1 |
| Gheysens, O | 1 |
| Nuyts, J | 3 |
| Verbruggen, A | 7 |
| Oyen, R | 4 |
| Alpizar, YA | 1 |
| Li, J | 5 |
| Bauwens, M | 3 |
| Talavera, K | 1 |
| de Witte, P | 4 |
| De Saint-Hubert, M | 2 |
| Deckers, N | 1 |
| Drummen, M | 1 |
| Douma, K | 1 |
| Granton, P | 1 |
| Hendrikx, G | 1 |
| Kusters, D | 1 |
| Bucerius, J | 1 |
| Reutelingsperger, CP | 1 |
| Mottaghy, FM | 2 |
| Jiang, B | 1 |
| Wang, J | 2 |
| Witte, Pd | 1 |
| Ji, Y | 2 |
| Zhan, Y | 1 |
| Wang, Q | 3 |
| Qi, X | 1 |
| Shao, H | 4 |
| Joniova, J | 1 |
| Misuth, M | 1 |
| Sureau, F | 1 |
| Miskovsky, P | 1 |
| Nadova, Z | 1 |
| Liu, X | 1 |
| Peng, F | 1 |
| Jing, S | 1 |
| Dai, X | 1 |
| Yang, S | 3 |
| Wang, C | 2 |
| Song, S | 2 |
| Chen, L | 1 |
| Gao, L | 1 |
| Ma, T | 1 |
| Shan, X | 1 |
| Prinsen, K | 1 |
| Mortelmans, L | 3 |
| Marysael, T | 3 |
| Lerut, E | 1 |
| Van de Putte, M | 4 |
| Fonge, H | 2 |
| Roskams, T | 1 |
| Bormans, G | 3 |
| de Witte, PA | 5 |
| Rozenski, J | 1 |
| Sharma, KV | 1 |
| Davids, LM | 2 |
| Du, HY | 2 |
| Olivo, M | 4 |
| Tan, BK | 1 |
| Bay, BH | 2 |
| Thong, PS | 1 |
| Watt, F | 1 |
| Ren, MQ | 1 |
| Tan, PH | 1 |
| Soo, KC | 2 |
| Yee, KK | 1 |
| Huyghe, D | 1 |
| Verbeke, K | 1 |
| Marchal, G | 1 |
| Verbruggen, AM | 1 |
| Bormans, GM | 1 |
| Yip, GW | 1 |
| Mikes, J | 1 |
| Kleban, J | 1 |
| Sacková, V | 1 |
| Horváth, V | 1 |
| Jamborová, E | 1 |
| Vaculová, A | 1 |
| Kozubík, A | 1 |
| Hofmanová, J | 1 |
| Fedorocko, P | 1 |
| Wang, H | 3 |
| Kleemann, B | 1 |
| Kacerovská, D | 1 |
| Pizinger, K | 1 |
| Kidson, SH | 1 |
| Vantieghem, A | 1 |
| Assefa, Z | 1 |
| Vandenabeele, P | 1 |
| Declercq, W | 1 |
| Courtois, S | 1 |
| Vandenheede, JR | 1 |
| Merlevede, W | 1 |
| Agostinis, P | 1 |
| Lavie, G | 1 |
| Kaplinsky, C | 1 |
| Toren, A | 1 |
| Aizman, I | 1 |
| Meruelo, D | 1 |
| Mazur, Y | 1 |
| Mandel, M | 1 |
| Mirossay, A | 1 |
| Mojzis, J | 1 |
| Tóthová, J | 1 |
| Hájiková, M | 1 |
| Lacková, A | 1 |
| Mirossay, L | 1 |
| Paba, V | 1 |
| Quarto, M | 2 |
| Varriale, L | 2 |
| Crescenzi, E | 1 |
| Palumbo, G | 2 |
| Coppola, E | 1 |
| Veneziani, BM | 1 |
2 reviews available for hypericin and Necrosis
| Article | Year |
|---|---|
Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging.
Topics: Anthracenes; Humans; Necrosis; Optical Imaging; Perylene; Staining and Labeling | 2013 |
Molecular imaging of cell death.
Topics: Animals; Annexin A5; Anthracenes; Antibodies, Monoclonal; Apoptosis; Bacteriocins; Cell Death; Gluca | 2009 |
38 other studies available for hypericin and Necrosis
| Article | Year |
|---|---|
Biodegradable Hypericin-Containing Nanoparticles for Necrosis Targeting and Fluorescence Imaging.
Topics: Animals; Anthracenes; Cell Line, Tumor; Female; Humans; Mice; Nanoparticles; Necrosis; Neoplasms; Op | 2020 |
Radioiodinated hypericin disulfonic acid sodium salts as a DNA-binding probe for early imaging of necrotic myocardium.
Topics: Animals; Anthracenes; Cattle; Cell Line; Cell Survival; DNA; Heart; Iodine Radioisotopes; Male; Mice | 2017 |
Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis.
Topics: Animals; Anthracenes; Area Under Curve; Half-Life; Iodine Isotopes; Isotope Labeling; Male; Necrosis | 2013 |
Comparative study of iodine-123-labeled hypericin and (99m)Tc-labeled hexakis [2-methoxy isobutyl isonitrile] in a rabbit model of myocardial infarction.
Topics: Animals; Anthracenes; Autoradiography; Coronary Circulation; Coronary Vessels; Disease Models, Anima | 2013 |
Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.
Topics: Animals; Anthracenes; Antineoplastic Agents; Chemistry, Pharmaceutical; Dimethyl Sulfoxide; Iodine R | 2014 |
In vivo molecular imaging of apoptosis and necrosis in atherosclerotic plaques using microSPECT-CT and microPET-CT imaging.
Topics: Animals; Annexin A5; Anthracenes; Apoptosis; Humans; Mice; Molecular Imaging; Multimodal Imaging; Ne | 2014 |
Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations.
Topics: Animals; Anthracenes; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Carriers; Fi | 2014 |
Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis.
Topics: Animals; Anthracenes; Disease Models, Animal; Iodine Radioisotopes; Liver; Magnetic Resonance Imagin | 2014 |
Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction.
Topics: Animals; Anthracenes; Autoradiography; Disease Models, Animal; Gamma Cameras; Heart; Iodine Radioiso | 2015 |
Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis.
Topics: Animals; Anthracenes; Catheter Ablation; Dogs; Liver; Male; Necrosis; Perylene; Radiopharmaceuticals | 2015 |
Effect of PKCα expression on Bcl-2 phosphorylation and cell death by hypericin.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Cell Survival; Gene Expression; Humans; Mitochondria; Necr | 2014 |
Evaluation of hypericin: effect of aggregation on targeting biodistribution.
Topics: Animals; Anthracenes; Antineoplastic Agents, Phytogenic; Autoradiography; Dimethyl Sulfoxide; Drug C | 2015 |
Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models.
Topics: Animals; Anthracenes; Antineoplastic Agents; Autoradiography; Carcinoma, Hepatocellular; Cell Line, | 2015 |
Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.
Topics: Animals; Anthracenes; Autoradiography; Disease Models, Animal; Iodine Radioisotopes; Necrosis; Neopl | 2015 |
Synthesis and Preclinical Evaluation of Radioiodinated Hypericin Dicarboxylic Acid as a Necrosis Avid Agent in Rat Models of Induced Hepatic, Muscular, and Myocardial Necroses.
Topics: Animals; Anthracenes; Iodine Radioisotopes; Liver; Muscle, Skeletal; Myocardial Infarction; Myocardi | 2016 |
Effects of skeleton structure on necrosis targeting and clearance properties of radioiodinated dianthrones.
Topics: Animals; Anthracenes; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Drug Design; | 2016 |
Discovery of Radioiodinated Monomeric Anthraquinones as a Novel Class of Necrosis Avid Agents for Early Imaging of Necrotic Myocardium.
Topics: Animals; Anthracenes; Anthraquinones; Chromatography, High Pressure Liquid; Iodine Radioisotopes; Ma | 2016 |
Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy.
Topics: Allografts; Animals; Anthracenes; Cell Line, Tumor; Combined Modality Therapy; Hyperthermia, Induced | 2016 |
Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Mice; Mice, Inbred C3H; Necrosis; Neo | 2011 |
Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential.
Topics: Animals; Anthracenes; Autoradiography; Female; Fibrosarcoma; Fluorodeoxyglucose F18; Mice; Mice, Inb | 2012 |
Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy.
Topics: Animals; Anthracenes; Antineoplastic Agents; Avidin; Biotin; Biotinylation; Cell Line, Tumor; Contra | 2012 |
Hypericin-PDT-induced rapid necrotic death in human squamous cell carcinoma cultures after multiple treatment.
Topics: Anthracenes; Carcinoma, Squamous Cell; Cell Line, Tumor; Humans; Hypericum; Necrosis; Perylene; Phot | 2012 |
Hypericin-mediated photodynamic therapy induces lipid peroxidation and necrosis in nasopharyngeal cancer.
Topics: Animals; Anthracenes; Antioxidants; Apoptosis; Cell Line, Tumor; Cytoplasm; Humans; Light; Lipid Per | 2003 |
Hypericin-photodynamic therapy (PDT) using an alternative treatment regime suitable for multi-fraction PDT.
Topics: Animals; Anthracenes; Apoptosis; Calcium; Immunohistochemistry; Light; Mice; Mice, Inbred BALB C; Mi | 2006 |
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Anthracenes; Celecoxib; Cyclooxygenase 2; Drug Therapy, Combinatio | 2005 |
First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent.
Topics: Animals; Anthracenes; Drug Evaluation, Preclinical; Heart; Liver; Metabolic Clearance Rate; Myocardi | 2006 |
Differential up-regulation of metallothionein isoforms in well-differentiated nasopharyngeal cancer cells in vitro by photoactivated hypericin.
Topics: Anthracenes; Flow Cytometry; Humans; In Vitro Techniques; Metallothionein; Nasopharyngeal Neoplasms; | 2006 |
Necrosis predominates in the cell death of human colon adenocarcinoma HT-29 cells treated under variable conditions of photodynamic therapy with hypericin.
Topics: Adenocarcinoma; Anthracenes; Caspase 3; Cell Cycle; Cell Proliferation; Colonic Neoplasms; Dose-Resp | 2007 |
Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model.
Topics: Analysis of Variance; Animals; Anthracenes; Antineoplastic Agents; Disease Models, Animal; Ethanol; | 2008 |
Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT.
Topics: Animals; Anthracenes; Disease Models, Animal; Drug Evaluation, Preclinical; Heart; Iodine Radioisoto | 2008 |
Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells.
Topics: Anthracenes; Apoptosis; Caspase 3; Caspase 7; Cell Death; Cell Line, Tumor; Cell Survival; Humans; I | 2008 |
Exploration of the mechanism underlying the tumor necrosis avidity of hypericin.
Topics: Animals; Anthracenes; Carbocyanines; Female; Fibrosarcoma; Lipoproteins; Mice; Mice, Inbred C3H; Nec | 2008 |
Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model.
Topics: Animals; Anthracenes; Biomarkers; Catheter Ablation; Female; Liver Neoplasms, Experimental; Mice; Mi | 2008 |
Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis.
Topics: Amino Acid Chloromethyl Ketones; Anthracenes; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Ce | 1998 |
A photodynamic pathway to apoptosis and necrosis induced by dimethyl tetrahydroxyhelianthrone and hypericin in leukaemic cells: possible relevance to photodynamic therapy.
Topics: Anthracenes; Apoptosis; bcl-2-Associated X Protein; Cell Nucleus; DNA, Neoplasm; Dose-Response Relat | 1999 |
Hypocrellin and hypericin-induced phototoxicity of HL-60 cells: apoptosis or necrosis?
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Drugs, Chinese Herbal; HL-60 Cells; Humans; Necrosis; | 2000 |
Photo-activation of hypericin with low doses of light promotes apparent photo-resistance in human histiocytic lymphoma U937 cells.
Topics: Anthracenes; Apoptosis; Cell Death; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm | 2001 |
Molecular aspects of photodynamic therapy: low energy pre-sensitization of hypericin-loaded human endometrial carcinoma cells enhances photo-tolerance, alters gene expression and affects the cell cycle.
Topics: Anthracenes; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Biological Transport; Carcinoma; | 2002 |